Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3960043 | 0.82 | GRM4 (0.37) | HDAC1HDAC2HDAC6HDAC3HDAC8 | |
| SCHEMBL19147779 | 0.81 | HDAC6 (0.33) | HDAC1HDAC2HDAC6HDAC3HDAC8 | |
| Hydrochloric Acid SCHEMBL31301903 | 0.80 | STING1 (0.36) | HDAC1HDAC2HDAC6HDAC3HDAC8 | |
| SCHEMBL29035595 | 0.79 | HDAC1 (0.32) | HDAC1HDAC2HDAC6HDAC3HDAC8 | |
| SCHEMBL5201745 | 0.79 | CYP1A2 (0.32) | — | |
| SCHEMBL328633 | 0.78 | STING1 (0.36) | HDAC1HDAC2HDAC6HDAC3HDAC8 | |
| SCHEMBL16334546 | 0.78 | STING1 (0.36) | HDAC1HDAC2HDAC6HDAC3HDAC8 | |
| SCHEMBL28026420 | 0.76 | STING1 (0.36) | HDAC1HDAC2HDAC6HDAC3HDAC8 | |
| SCHEMBL16751457 | 0.76 | LMNA (0.36) | HDAC1HDAC2HDAC6HDAC3HDAC8 | |
| SCHEMBL19001556 | 0.75 | STING1 (0.31) | STING1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2751141-B1 | STABLE PEPTIDE-BASED PACE4 INHIBITORS | SOCPRA SCIENCES SANTE ET HUMAINES S E C (CA) | 2018-03-21 | — | — | EP | disclosed |
| US-9809621-B2 | Stable peptide-based PACE4 inhibitors | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2017-11-07 | — | — | US | disclosed |
| US-20150141324-A1 | STABLE PEPTIDE-BASED FURIN INHIBITORS | SOCPRA Sciences Sante et Humaines S.E.C. (CA) | 2015-05-21 | — | — | US | disclosed |
| US-9017673-B2 | Peptide analogues comprising at least one type of aminoacylaza-$g(b)<sp>3</sp>and the use thereof, in particular for therapy | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2015-04-28 | — | — | US | disclosed |
| EP-2776471-A1 | STABLE PEPTIDE-BASED FURIN INHIBITORS | Socpra Sciences Santé Et Humaines S.E.C. (CA) | 2014-09-17 | — | — | EP | disclosed |
| US-20140206622-A1 | STABLE PEPTIDE-BASED PACE4 INHIBITORS | SOCPRA Sciences Sante et Humaines S.E.C. (CA) | 2014-07-24 | — | — | US | disclosed |
| EP-2751141-A1 | STABLE PEPTIDE-BASED PACE4 INHIBITORS | Socpra Sciences Santé Et Humaines S.E.C. (CA) | 2014-07-09 | — | — | EP | disclosed |
| WO-2013029180-A1 | STABLE PEPTIDE-BASED PACE4 INHIBITORS | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013029182-A1 | STABLE PEPTIDE-BASED FURIN INHIBITORS | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2013-03-07 | — | — | WO | disclosed |
| US-20110044974-A1 | Peptide analogues comprising at least one type of aminoacylaza-$g(b)<sp>3</sp>and the use thereof, in particular for therapy | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2011-02-24 | — | — | US | disclosed |
| EP-1631586-B1 | PEPTIDE ANALOGUES COMPRISING AT LEAST ONE TYPE OF AMINOACYL AZA-BETA 3 AND THE USE THEREOF, IN PARTICULAR FOR THERAPY | CENTRE NAT RECH SCIENT (FR) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141324-A1 | STABLE PEPTIDE-BASED FURIN INHIBITORS | FURIN, PREP, VIP | HDAC1 1185/4885HDAC2 2110/4885HDAC6 1423/4885 |
| US-20140206622-A1 | STABLE PEPTIDE-BASED PACE4 INHIBITORS | FURIN, DNPEP, PRAP1 | HDAC1 1946/4885HDAC2 3082/4885HDAC6 1209/4885 |
| US-20110044974-A1 | Peptide analogues comprising at least one type of aminoacylaza-$g(b)<sp>3</sp>and the use thereof, in particular for therapy | ANPEP, NPPA, DPP3 | HDAC1 1073/4885HDAC2 2919/4885HDAC6 455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.